Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Easy quantitation of receptor activity by measuring luciferase activity High-throughput screening and profiling of inhibitors, blocking antibodies or activators for drug discovery Compliment with our Luciferase assay systems for sensitive and rapid detection of luciferase activity GLP-1R/CRE Luciferase Reporter HEK293 Cell Line GLP-1R/CRE Luciferase Reporter HEK293 Cell Line is an engineered HEK293 cell line expressing firefly luciferase under the control of cAMP response element (CRE), and human GLP-1R (Glucagon-like peptide 1 receptor
Athauda, D
As with any medication, adjusting to GLP-1 therapy can come with some side effects, particularly digestive issues like nausea, diarrhea, and constipation
Risk factors that may prompt additional consideration include: Active gastrointestinal symptoms (nausea, vomiting, abdominal pain) Recent dose increases or being in the dose-escalation phase Higher doses of semaglutide Known gastroparesis or other conditions affecting gastric emptying Obesity with GERD or hiatal hernia Based on the 2024 multi-society guidance, most patients can continue GLP-1 receptor agonists before elective procedures with appropriate risk assessment and mitigation strategies, rather than automatic postponement
However, behind its effectiveness lie non-negligible risks such as gastrointestinal side effects, pancreatitis, cholecystitis, loss of muscle mass, and rebound weight gain
US$ 26.24
US$ 24.15
US$ 21.43
US$ 27.92
US$ 27.02
US$ 21.80
US$ 27.53
